Treatment Registry
TR-0634 ActiveRecorded September 2026Last verified October 2026

Compounded tirzepatide

Sold by Immortals · every compounded tirzepatide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

Price

TermPublished rateCharged today
Compounded Tirzepatide with Glycine and B12

Price conditions have not been established; the quoted figure is not a verified recurring rate.

“Compounded Tirzepatide with Glycine and B12 From $180/mo* Activates both GLP-1 and GIP receptors, the two gut hormones that signal appetite and satiety.”

$180Published figureCharged todayNot verified
Price sources
Visit Immortals

We earn nothing from this link. It opens Immortals's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyNot disclosed
StatesNot disclosed
PrescriberBoth
CancellationCancel future subscription charges in account settings at least 24 hours before the current subscription period ends. Cancellation takes effect at the end of that period. Medicine sales are final, with no returns or refunds; contact support about a dispensing error.
MembershipNone. “We sell medicine not memberships.”
Consult feeNot disclosed

Recorded from immortals.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. October 2026 — Immortals lists monthly equivalents for plans billed quarterly with a three-month commitment paid upfront. The exact checkout total is not established by multiplying a rounded starting monthly figure. There is no membership fee. Clinicians review an online intake, with an audio or video consultation where state rules require it. The medicine refund policy treats prescription sales as final.

2 further notes concern other Immortals programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0634
Medication category
compounded tirzepatide
Readings
3

Related records

Cite this entry

Treatment Registry. (2026). Immortals — compounded tirzepatide (TR-0634). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0634

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.